AeroRx Presents Positive Phase 2a Data for Inhaled AERO-007, the First Potential Nebulized LABA+LAMA Fixed-Dose Combination ...
Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to improving the lives of people with chronic lung diseases including COPD and asthma, demonstrated positive results from its ...
About 40% of at-risk patients with COPD did not receive maintenance therapy despite having frequent or severe exacerbations.
Among hospitalized adults with acute exacerbation of COPD, pegtarazimod improved oxygen utilization and inflammatory ...
Lupin has received tentative approval from the Food and Drug Administration for revefenacin inhalation solution, 175 mcg/3 ml unit-dose vials, which is the generic of Mylan's Yupelri inhalation ...
Pairing vulnerable, low-income patients with asthma coaches can improve outcomes and may also reduce costs associated with ...
The drug tezepelumab was shown to significantly reduce exacerbations in people with severe asthma in clinical trials. Now, a ...
Lupin received US FDA tentative approval for Revefenacin Inhalation Solution (175 mcg/3 mL), bioequivalent to Yupelri, ...
Treating COPD and Asthma with Targeted Lung Denervation is Focus of Mini-Symposium MILAN, Italy, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Nuvaira ( a developer ...
Woman's World on MSN
This COPD medication may reverse fatty liver disease in just four weeks
Like high blood pressure, fatty liver disease has a way of sneaking up on people, often not causing noticeable symptoms until ...
The drug tezepelumab was shown to significantly reduce exacerbations in people with severe asthma in clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results